GlassScriptPhysician profile
Evangeline Reyes
NPI 1144224908
$17,417.96
in general payments reported to CMS, 2019-2025
76 companies · $25.43 in 2025
The $25.43 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,825 · 2020: $2,538 · 2021: $2,884 · 2022: $4,009 · 2023: $4,359 · 2024: $778 · 2025: $25.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,842.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,317.96 | 2019-2024 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,289.01 | 2019-2024 | Opdivo |
| Genzyme Corporation | $984.29 | 2019-2023 | |
| Glaxosmithkline, LLC. | $787.25 | 2020-2024 | Zejula, Ojjaara, Shingrix |
| Janssen Biotech, INC. | $774.56 | 2020-2024 | Darzalex, Imbruvica, Tecvayli |
| Celgene Corporation | $689.33 | 2019-2024 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $649.73 | 2019-2023 | Calquence, Imfinzi, Lynparza |
| Pfizer INC. | $600.27 | 2019-2023 | |
| Amgen INC. | $575.72 | 2019-2023 | Kyprolis, Blincyto |
| Seagen INC. | $539.80 | 2019-2023 | Adcetris, Tivdak, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $522.18 | 2019-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $480.88 | 2019-2023 | Jakafi |
| Astellas Pharma US INC | $359.10 | 2020-2024 | Xtandi, Xospata, Padcev |
| Genentech USA, INC. | $336.88 | 2019-2023 | Tecentriq, Polivy |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evangeline Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.